WO2024142934A1 - 塗布型皮膜形成剤、及び該形成剤を含むキット - Google Patents

塗布型皮膜形成剤、及び該形成剤を含むキット Download PDF

Info

Publication number
WO2024142934A1
WO2024142934A1 PCT/JP2023/044605 JP2023044605W WO2024142934A1 WO 2024142934 A1 WO2024142934 A1 WO 2024142934A1 JP 2023044605 W JP2023044605 W JP 2023044605W WO 2024142934 A1 WO2024142934 A1 WO 2024142934A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
less
hydride
terminated
film
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2023/044605
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
喜郎 貞神
恭平 小坂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Priority to JP2024567450A priority Critical patent/JPWO2024142934A1/ja
Publication of WO2024142934A1 publication Critical patent/WO2024142934A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/25Silicon; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31Hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/89Polysiloxanes
    • A61K8/891Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/89Polysiloxanes
    • A61K8/895Polysiloxanes containing silicon bound to unsaturated aliphatic groups, e.g. vinyl dimethicone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00Make-up preparations; Body powders; Preparations for removing make-up
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Definitions

  • the present disclosure relates to a coating-type film-forming agent and a kit containing the agent.
  • a coating-type film-forming agent such as that described in Patent Document 1
  • a film is formed on the skin surface.
  • the formed film is not permanently applied to the skin and is typically removed from the skin after a certain period of time has passed.
  • the subject of this disclosure is therefore to provide a coat-type film-forming agent that can make the formed film easier to peel off from the skin and can reduce or prevent contamination of the surroundings caused by the peeled off film.
  • Aspect 3 The forming agent according to aspect 1 or 2, wherein the inorganic oxide constituting the hydrophobized inorganic oxide particles is at least one selected from the group consisting of silicon oxide, titanium oxide, and zinc oxide.
  • ⁇ Aspect 9> The forming agent according to any one of the preceding aspects, wherein the catalyst is at least one selected from the group consisting of platinum catalysts, rhodium catalysts, and tin catalysts.
  • the catalyst is a platinum catalyst, and the platinum catalyst is at least one selected from the group consisting of platinum carbonylcyclovinylmethylsiloxane complex, platinum divinyltetramethyldisiloxane complex, platinum cyclovinylmethylsiloxane complex, and platinum octanaldehyde/octanol complex.
  • ⁇ Aspect 11> A kit, in which the first agent and the second agent in the forming agent according to any one of aspects 1 to 10 are contained in separate containers, or are contained separately in each compartment of a container having two or more compartments.
  • the present disclosure provides a coating-type film-forming agent that can easily peel off the formed film from the skin and reduce or prevent contamination of the surrounding area caused by the peeled off film.
  • the films formed by the coating-type film-forming agents described in Patent Document 1 typically have a cross-linked structure, and are therefore considered to have superior strength (e.g., toughness) compared to films that do not have a cross-linked structure. However, even such films do not have sufficient strength, and there are cases in which the film breaks when peeled off from the skin, as shown in the photograph on the left side of Figure 1.
  • the unsaturated organopolysiloxane and hydride-functionalized polysiloxane typically have hydrophobic properties, and for example, the first agent may also contain oils such as dimethicone. It is believed that the hydrophobized inorganic oxide particles are compatible with hydrophobic components such as these film components, and therefore can be uniformly dispersed in the film components. In addition, because the particles are nano-sized, it is believed that the particles are more uniformly distributed in the film that is formed.
  • hydrophobic inorganic oxide particles of a specified size are uniformly distributed in a specified ratio in the film, and the number of cross-linking points in the cross-linking structure of the film is increased, which is believed to have improved the strength (e.g., toughness) of the film.
  • a “body correction coating” refers to a coating that is intended to provide a natural skin appearance when applied to the skin of a subject.
  • natural skin appearance means that when applied to the skin, the body correction coating provides similar or identical performance to at least one of the appearance, feel, and texture of actual skin, e.g., the treated skin can provide the physical properties (e.g., elasticity and firmness) of actual (e.g., current) skin.
  • body correction means to mask, conceal or cover a body or skin imperfection of a subject to visually and/or tactilely improve the body or skin imperfection, but does not include methods of surgery, treatment or diagnosis of a human.
  • body imperfection can mean, for example, such part of the subject's body that the subject perceives as a blemish or blemish, or that a person skilled in the art, e.g., a dermatologist, esthetician or plastic surgeon, would consider to be a blemish or blemish.
  • nevus flammeus or nevus flameus e.g., hemangioma simplex or midline nevus flammeus
  • melasma wrinkles, age spots
  • acne moles
  • scars tattoos
  • birthmarks skin deformities
  • birthmarks sun damage
  • aging uneven skin tone, loose skin, rough skin, hyperpigmentation, enlarged pores, telangiectasias, redness, shine, cellulite, stretch marks, or reduced skin elasticity.
  • the application performance of the paint-on film-forming agent can be evaluated by viscosity using a Brookfield viscometer (Shibaura Systems Co., Ltd., Vismetron).
  • the viscosity of the first and second agents in the paint-on film-forming agent of the present disclosure immediately after preparation, measured under conditions of 25°C and 60 rpm (rotor No. 3 or No. 4), is, for example, 100 mPa ⁇ s or more, 500 mPa ⁇ s or more, 1,000 mPa ⁇ s or more, 2,000 mPa ⁇ s or more, 5,000 mPa ⁇ s or more, 7,500 mPa ⁇ s or more, 10,000 mPa ⁇ s or more, or 15,000 mPa ⁇ s.
  • the first unsaturated organopolysiloxane is not particularly limited, and may be an organopolysiloxane having an unsaturated portion, for example, one or more organopolysiloxanes having at least two carbon-carbon double bonds or at least one carbon-carbon triple bond in the molecule.
  • an unsaturated organopolysiloxane preferably, one or more organopolysiloxanes having at least two alkenyl functional groups (e.g., vinyl functional groups) on average and having a viscosity of 1,000 to 2,000,000 cst at 25°C may be mentioned.
  • one, two, three, four, five or six of R 1b , R 2b , R 3b , R 6b , R 7b and R 8b may be C 1-20 alkyl.
  • At least one of the first and second agents in the coating-type film-forming agent of the present disclosure contains hydrophobized inorganic oxide particles having an average primary particle size of less than 1,000 nm. From the viewpoint of obtaining good film strength, such particles are preferably contained in the first agent, and more preferably contained only in the first agent.
  • the hydrophobized inorganic oxide particles can be used alone or in combination of two or more kinds.
  • the average primary particle diameter of the hydrophobized inorganic oxide particles can mean, for example, the particle diameter when converted into a circular particle having the same area as the projected area of the particle observed with a transmission electron microscope (area-equivalent circle particle diameter).
  • the area-equivalent circle particle diameter can be defined as the average value of 10 or more particles.
  • cosmetic agents include moisturizers, UV absorbers, skin protectants, skin soothing agents, skin whitening agents, skin glossing agents, skin softeners, skin smoothing agents, skin bleaching agents, skin exfoliating agents, skin tightening agents, beauty agents, vitamins, antioxidants, cell signaling agents, cell regulating agents, cell interacting agents, skin tanning agents, anti-aging agents, anti-wrinkle agents, spot reducers, alpha-hydroxy acids, beta-hydroxy acids, and ceramides; and also include, for example, pain relieving agents, analgesics, anti-pruritic agents, anti-acne agents (e.g., beta-hydroxy acids, salicylic acid, benzoyl peroxide), and anti-inflammatory agents.
  • analgesics e.g., analgesics, anti-pruritic agents, anti-acne agents (e.g., beta-hydroxy acids, salicylic acid, benzoyl peroxide), and anti-inflammatory agents.
  • the therapeutic agents may include, for example, antihistamines, corticosteroids, NSAIDs (nonsteroidal anti-inflammatory drugs), antiseptics, antibiotics, antibacterials, antifungals, antivirals, antiallergy agents, anti-irritants, insect repellents, phototherapy agents, blood clotting agents, antineoplastic agents, immune system enhancers, immune system suppressants, coal tar, anthralin, fluocinonide, methotrexate, cyclosporine, pimecrolimus, tacrolimus, azathioprine, fluorouracil, ceramides, counterirritants, and skin cooling compounds; and may include, for example, antioxidants, vitamins, vitamin D3 analogs, retinoids, minerals, mineral oil, petrolatum, fatty acids, plant extracts, polypeptides, antibodies, proteins, sugars, humectants, and emollients.
  • NSAIDs nonsteroidal anti-inflammatory drugs
  • antiseptics antibiotics
  • oils include liquid oils, solid oils, waxes, hydrocarbon oils, silicone oils, and polar oils.
  • the oils may be non-volatile or volatile oils.
  • the oils may be used alone or in combination.
  • volatile refers to oils that exhibit a volatile content of more than 5% when left at atmospheric pressure and 105°C for 3 hours. Such volatile content can be specified as 10% or more, 20% or more, 40% or more, 50% or more, 60% or more, 80% or more, or 100%.
  • the boiling point at 1 atmosphere (101.325 kPa) can be used as an indicator of volatility.
  • silicone surfactants include polyether-modified silicone and alkyl-co-modified polyether-modified silicone.
  • the amount of emulsifier used can be 0.01% by mass or more, 0.05% by mass or more, 0.1% by mass or more, or 0.2% by mass or more relative to the total amount of the first or second agent.
  • the upper limit of the amount of emulsifier used can be, for example, 5.0% by mass or less, 4.0% by mass or less, 3.0% by mass or less, 2.0% by mass or less, or 1.0% by mass or less.
  • the method of using the applied-type film-forming agent of the present disclosure is not particularly limited, and may include, for example, any of the following steps.
  • makeup can be applied to the face, and therefore the method can also be called a makeup method.
  • the preferred method of use is to apply the first agent to the skin to form a first agent layer, and then apply the second agent onto this first agent layer and crosslink it to form a coating.
  • the materials described above can be used for the first agent and the second agent in the same manner.
  • This method may be performed once, or may be performed multiple times (e.g., two or more times, or three or more times) on the formed coating.
  • the method may include, for example, any of the following operations: A process of applying a first agent to the formed coating to form a first agent layer, and then applying a second agent onto the first agent layer to further form a coating; or An operation of applying a second agent to the formed coating to form a second agent layer, and then applying a first agent onto the second agent layer to further form a coating; or an operation of mixing the first agent and the second agent to prepare a mixture, and then applying the mixture to the formed coating to further form a coating.
  • cosmetics there are no particular limitations on the cosmetics that can be used, and examples of such cosmetics include skin care cosmetics such as serums, lotions, and emulsions, sunscreen cosmetics (sun protection cosmetics), base cosmetics, or make-up cosmetics such as foundations, glosses, lipsticks, eye shadows, and nail polishes, or cosmetics that combine the functions of two or more of these cosmetics.
  • skin care cosmetics such as serums, lotions, and emulsions
  • sunscreen cosmetics unsun protection cosmetics
  • base cosmetics such as foundations, glosses, lipsticks, eye shadows, and nail polishes, or cosmetics that combine the functions of two or more of these cosmetics.
  • make-up cosmetics such as foundations, glosses, lipsticks, eye shadows, and nail polishes, or cosmetics that combine the functions of two or more of these cosmetics.
  • the occlusion effect of the film allows the skin to be well moisturized.
  • the skin's own production function of moisturizing ingredients is improved, and turnover problems in the stratum corneum are also improved, making skin problems such as roughness less likely to occur, and improving the cosmetic effect.
  • the term "cosmetic method" refers to applying the applied film-forming agent of the present disclosure to the skin to form a film and beautify the skin's condition, or a method for beautifying the skin's condition, and is different from a method of surgery, treatment, or diagnosis of humans.
  • the weight average molecular weight of the polar oil is preferably 265 or more or 270 or more, and is preferably 390 or less, 380 or less, or 370 or less, from the viewpoint of suitable removal of the film.
  • the IOB value of the polar oil is preferably 0.12 or more or 0.13 or more, and is preferably 1.48 or less, 1.47 or less, or 1.46 or less, from the viewpoint of suitable removal of the film.
  • the polar oil can be used alone or in combination of two or more kinds.
  • the IOB value is an abbreviation for Inorganic/Organic Balance (inorganic/organic ratio), and is a value that represents the ratio of the inorganic value to the organic value, and is an index that indicates the degree of polarity of an organic compound.
  • the amount of polar oil blended can be 1.0 mass% or more, 5.0 mass% or more, 10 mass% or more, 15 mass% or more, or 20 mass% or more relative to the total amount of the composition constituting the remover.
  • the upper limit of the blended amount can be, for example, 100 mass% or less, less than 100 mass%, 80 mass% or less, 70 mass% or less, 60 mass% or less, or 50 mass% or less.
  • the remover of the present disclosure may contain oils other than the above-mentioned hydrocarbon oils and polar oils.
  • silicone oils may reduce the strength of the film, and as a result, may reduce the film removal performance. Therefore, from the viewpoint of effectively removing the film, the amount of silicone oil is preferably 10 mass % or less, 5.0 mass % or less, 1.0 mass % or less, 0.5 mass % or less, or 0.1 mass % or less relative to the total amount of the composition constituting the remover, and it is more preferable that silicone oil is not included in the composition constituting the remover.
  • the remover can be applied to a part or the whole of the film formed on the body surface, and then optionally rubbed. Then, the film can be removed by pulling the film that has peeled off from the body surface with a finger or the like.
  • ⁇ Film removal test Film removal performance> The first and second agents of the test sample were applied in sequence to the backs of the hands of five expert panelists to form films, and 15 minutes later, the films were peeled off with the fingers to evaluate film removal performance according to the following criteria.
  • an A rating can be considered as a pass
  • B and C ratings can be considered as a fail.
  • “the film could be peeled off in one go” means that it could be peeled off in the state shown in the photograph on the right side of Figure 1: (Evaluation criteria)
  • A Four or more of the five expert panelists evaluated that the coating could be peeled off in one go.
  • B Two to three of the five expert panelists evaluated that the coating could be peeled off in one go.
  • C One or less of the five expert panelists evaluated that the coating was able to be peeled off in one go.
  • Test Example 1 Each test sample in Test Example 1 was prepared according to the following method.
  • Test Example 1 the effects on film removal performance based on the presence or absence of hydrophobization treatment and differences in average primary particle size of inorganic oxide particles, as well as the effect on film removal performance of the mass ratio of the total amount of inorganic oxide particles to the total amount of unsaturated organopolysiloxane were investigated. The results are shown in Table 1.
  • Example 1 (First Agent) A first agent was prepared by uniformly mixing 40.5 parts by weight of vinyl dimethicone as the first unsaturated organopolysiloxane, 7.9 parts by weight of hydrogen dimethicone as the first hydride-functionalized polysiloxane, 33.4 parts by weight of dimethicone, and 18.2 parts by weight of hydrophobically treated silica particles.
  • the second agent was prepared by uniformly mixing 1.0 part by mass of the mixture of vinyl dimethicone, divinyl disiloxane and platinum catalyst, 20.0 parts by mass of isododecane, and 79.0 parts by mass of dimethicone. Note that, since the amounts of vinyl dimethicone and divinyl disiloxane contained in the mixture containing the platinum catalyst are small, they are not taken into consideration in the calculation of the "mass ratio of the total amount of silica particles to the total amount of vinyl dimethicone" in Table 1.
  • Example 2 to 6 and Comparative Examples 1 to 6 The first and second agents were prepared in the same manner as in Example 1, except that the blending amounts of each component in the first agent were changed to the ratios shown in Table 1.
  • Test Example 2 In Test Example 2, the influence of different removers on film removal performance was examined. The results are shown in Tables 2 to 4. In Test Example 2, the paint-on film-forming agent of Example 1 was used, and each of the oils listed in Tables 2 to 4 was used as a remover. In the film removal test described above, the remover was applied to the entire film two hours after the film was formed, and the peeled film was peeled off with fingers, and the film removal performance was evaluated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Paints Or Removers (AREA)
PCT/JP2023/044605 2022-12-27 2023-12-13 塗布型皮膜形成剤、及び該形成剤を含むキット Ceased WO2024142934A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024567450A JPWO2024142934A1 (https=) 2022-12-27 2023-12-13

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022210064 2022-12-27
JP2022-210064 2022-12-27

Publications (1)

Publication Number Publication Date
WO2024142934A1 true WO2024142934A1 (ja) 2024-07-04

Family

ID=91717707

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/044605 Ceased WO2024142934A1 (ja) 2022-12-27 2023-12-13 塗布型皮膜形成剤、及び該形成剤を含むキット

Country Status (2)

Country Link
JP (1) JPWO2024142934A1 (https=)
WO (1) WO2024142934A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536861A (ja) * 2010-08-31 2013-09-26 リビング プルーフ,インコーポレーテッド 皮膚用組成物およびその使用方法
JP2015061881A (ja) * 2014-12-25 2015-04-02 株式会社 菊星 ヘアスタイリング剤組成物
US20180296591A1 (en) * 2011-09-21 2018-10-18 Shiseido Americas Corporation Compositions and methods for treating conditions of compromised skin barrier function
WO2021187276A1 (ja) * 2020-03-17 2021-09-23 株式会社 資生堂 人工皮膚形成用組成物、及びその使用方法
WO2022215533A1 (ja) * 2021-04-07 2022-10-13 株式会社 資生堂 第1剤及び第2剤を含む塗布型身体補正皮膜形成剤の第2剤、並びに身体補正皮膜に適用される潤滑層形成剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536861A (ja) * 2010-08-31 2013-09-26 リビング プルーフ,インコーポレーテッド 皮膚用組成物およびその使用方法
US20180296591A1 (en) * 2011-09-21 2018-10-18 Shiseido Americas Corporation Compositions and methods for treating conditions of compromised skin barrier function
JP2015061881A (ja) * 2014-12-25 2015-04-02 株式会社 菊星 ヘアスタイリング剤組成物
WO2021187276A1 (ja) * 2020-03-17 2021-09-23 株式会社 資生堂 人工皮膚形成用組成物、及びその使用方法
WO2022215533A1 (ja) * 2021-04-07 2022-10-13 株式会社 資生堂 第1剤及び第2剤を含む塗布型身体補正皮膜形成剤の第2剤、並びに身体補正皮膜に適用される潤滑層形成剤

Also Published As

Publication number Publication date
JPWO2024142934A1 (https=) 2024-07-04

Similar Documents

Publication Publication Date Title
JP5139899B2 (ja) ポリエーテルシロキサンコポリマー網目構造組成物
US9937200B2 (en) Skin compositions and methods of use thereof
JP4647190B2 (ja) ポリエーテルシロキサンコポリマー網目構造組成物を用いた化粧品組成物
CN105916489B (zh) 化妆品组合物
JP4229548B2 (ja) 化粧品、および化粧品の製造方法
EP3223775B1 (fr) Gel aqueux ou hydroalcoolique de phyllosilicates synthetiques a titre d'agent viscosant, matifiant et/ou homogeneisant d'application
US20240156692A1 (en) Oil-in-water composition for second agent for coating-type body corrective film formation agent
JP7720830B2 (ja) 人工皮膚形成用組成物、及びその使用方法
JP2009516025A (ja) 膨張性シリコーン組成物及びその調製方法
JP7815143B2 (ja) 白金触媒を含む水中油型乳化組成物、及びその使用方法
US20180064630A1 (en) Pituitous silicone fluid composition
WO2022215533A1 (ja) 第1剤及び第2剤を含む塗布型身体補正皮膜形成剤の第2剤、並びに身体補正皮膜に適用される潤滑層形成剤
CN108623810B (zh) 一种有机硅交联聚合物及其制备方法和应用
US9498409B2 (en) Cosmetic skin covering sheets and their method of preparation
US9744119B2 (en) Cosmetic composition and method of preparation
US11497704B2 (en) Agent for forming film on skin
JP2019518837A (ja) 架橋ポリオルガノシロキサン及びそれを含むパーソナルケア組成物
WO2024142934A1 (ja) 塗布型皮膜形成剤、及び該形成剤を含むキット
WO2023037984A1 (ja) 塗布型身体補正皮膜形成剤
JP6832853B2 (ja) 化粧品組成物および調製方法
WO2025105223A1 (ja) 塗布型皮膜形成剤、及び該形成剤を含むキット
WO2024090246A1 (ja) 唇用塗布型皮膜形成剤及び該形成剤の使用方法
WO2024154597A1 (ja) 塗布型皮膜形成剤の第2剤用水中油型組成物
WO2022030284A1 (ja) 塗布型身体補正皮膜用の下地剤、及びその使用方法
WO2025105304A1 (ja) 塗布型皮膜形成剤、該形成剤を含むキット、及び該形成剤の使用方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23911715

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2024567450

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23911715

Country of ref document: EP

Kind code of ref document: A1